Borrelia C6 ELISA, Serum
Orderable by Ontario ND
Test
Clinical Utility
The use of the recombinant outer surface protein A (rOspA) vaccine (LYMErix; GlaxoSmithKline) confounds Lyme antibody testing as most methods detect OspA antibodies. A method that does not detect OspA antibodies is required for patients who might have received an OspA-based vaccine.
Source: Marques, A. R., Martin, D. S., & Philipp, M. T. (2002). Evaluation of the C6 Peptide Enzyme-Linked Immunosorbent Assay for Individuals Vaccinated with the Recombinant OspA Vaccine.Journal of Clinical Microbiology,40(7), 2591-2593. http://doi.org/10.1128/JCM.40.7.2591-2593.2002
This Borrelia C6-peptide ELISA utilizes such a method and can be used to diagnose Lyme disease in patients who have received the OspA vaccine. The assay is based on a peptide (C6) that reproduces the sequence of the invariable region 6 (IR6) of the VlsE (Vmp-like sequence, expressed) lipoprotein. It has been reported to be a sensitive and specific test for the serologic diagnosis of Lyme disease.
Method
ELISA
Result Included
- Borrelia burgdorferi C6 ELISA
Test Location
ArminLabs
Specimen
Specimen Type
SerumCollection & Handling
Handling Information
Do not refrigerate or centrifuge. Protect from direct sunlight.
Additional Information
A specimen collection kit is available. To order a kit online, please register or login. For assistance or more information, please click here to send us an email or call 416-422-3000 x 300.
Stability
| Ambient |
|---|
| 14 Days |
Sample Report
Turnaround Time
7 Days
Sample Report
Test Version
Last Updated
2019-09-30